The treg/Th17 paradigm in lung cancer

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Duan, Min Chao ^a   Zhong, Xiao Ning ^b   Liu, Guang Nan ^b   Wei, Jin Ru ^c  

^a The Eighth People s Hospital of Nanning   (China)

^b FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^c First People's Hospital of Nanning   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; ORPHAN NUCLEAR RECEPTOR; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ANTIGEN PRESENTATION; APOPTOSIS; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL CYCLE REGULATION; CYTOKINE PRODUCTION; DISEASE COURSE; HOST RESISTANCE; HUMAN; LUNG CANCER; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE ACTIVATION; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PLEIOTROPY; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; BIOSYNTHESIS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LIVER TUMOR; LUNG; NON SMALL CELL LUNG CANCER; PATHOLOGY; TH1 TH2 BALANCE;

CARCINOMA, NON-SMALL-CELL LUNG; CYTOKINES; HUMANS; IMMUNE TOLERANCE; LIVER NEOPLASMS; LUNG; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH1-TH2 BALANCE; TH17 CELLS; TH2 CELLS;

EID: 84901020266     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/730380     Document Type: Review

References (119)

1. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D., Global cancer statistics. CA: A Cancer Journal for Clinicians 2011 61 2 69 90 2-s2.0-79952232216 10.3322/caac.20107
2. Reddy C., Chilla D., Boltax J., Lung cancer screening: a review of available data and current guidelines. Hospital Practice 2011 39 4 107 112 2-s2.0-84856136119
3. Alberg A. J., Brock M. V., Ford J. G., Samet J. M., Spivack S. D., Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013 143 supplement 5 e1S e29S
4. Ellis J., The impact of lung cancer on patients and carers. Chronic Respiratory Disease 2012 9 1 39 47 2-s2.0-84856702976 10.1177/1479972311433577
5. Milara J., Cortijo J., Tobacco, inflammation, and respiratory tract cancer. Current Pharmaceutical Design 2012 18 26 3901 3938 10.2174/ 138161212802083743
6. Houghton A. M., Mechanistic links between COPD and lung cancer. Nature Reviews Cancer 2013 13 4 233 245 10.1038/nrc3477
7. Brenner D. R., McLaughlin J. R., Hung R. J., Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLoS ONE 2011 6 3 2-s2.0-79953305328 10.1371/journal.pone.0017479 e17479
8. O'Callaghan D. S., O'Donnell D., O'Connell F., O'Byrne K. J., The role of inflammation in the pathogenesis of non-small cell lung cancer. Journal of Thoracic Oncology 2010 5 12 2024 2036 2-s2.0-78650434229 10.1097/JTO. 0b013e3181f387e4
9. Khuder S. A., Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer 2001 31 2-3 139 148 2-s2.0-0035144711 10.1016/S0169-5002(00)00181-1 (Pubitemid 32107010)
10. Pesch B., Kendzia B., Gustavsson P., Jöckel K.-H., Johnen G., Pohlabeln H., Olsson A., Ahrens W., Gross I. M., Brüske I., Wichmann H.-E., Merletti F., Richiardi L., Simonato L., Fortes C., Siemiatycki J., Parent M.-E., Consonni D., Landi M. T., Caporaso N., Zaridze D., Cassidy A., Szeszenia-Dabrowska N., Rudnai P., Lissowska J., Stücker I., Fabianova E., Dumitru R. S., Bencko V., Foretova L., Janout V., Rudin C. M., Brennan P., Boffetta P., Straif K., Brüning T., Cigarette smoking and lung cancer-relative risk estimates for the major histological types from a pooled analysis of case-control studies. International Journal of Cancer 2012 131 5 1210 1219 2-s2.0-83355175877 10.1002/ijc.27339
11. Swartz M. A., Iida N., Roberts E. W., Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Research 2012 72 2473 2480 10.1158/0008-5472.CAN-12-0122
12. Nelson D., Ganss R., Tumor growth or regression: powered by inflammation. Journal of Leukocyte Biology 2006 80 4 685 690 2-s2.0-33751505042 10.1189/jlb.1105646 (Pubitemid 44835882)
13. Imahayashi S., So T., Sugaya M., Yasuda M., Eifuku R., Takenoyama M., Hanagiri T., Yoshimatsu T., Oyama T., Yasumoto K., Establishment of an immortalized T-cell line from lung cancer tissue: phenotypic and functional analyses. International Journal of Clinical Oncology 2002 7 1 38 44 2-s2.0-6444244718 (Pubitemid 34289912)
14. Abbas A. K., Murphy K. M., Sher A., Functional diversity of helper T lymphocytes. Nature 1996 383 6603 787 793 2-s2.0-0029847368 10.1038/383787a0 (Pubitemid 26372655)
15. Weaver C. T., Hatton R. D., Interplay between the TH 17 and TReg cell lineages: a (co-)evolutionary perspective. Nature Reviews Immunology 2009 9 12 883 889 2-s2.0-72949106340 10.1038/nri2660
16. + memory T cells: functional modules for tailored immunity. European Journal of Immunology 2009 39 8 2076 2082 2-s2.0-70249100293 10.1002/eji.200939722
17. + T cells in lung cancer through hypermethylation: a possible mechanism of tumor-induced immunosuppression. PLoS ONE 2013 8 11 e79064
18. Ito N., Nakamura H., Tanaka Y., Ohgi S., Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry. Cancer 1999 85 11 2359 2367 (Pubitemid 29244844)
19. Bettelli E., Korn T., Kuchroo V. K., Th17: the third member of the effector T cell trilogy. Current Opinion in Immunology 2007 19 6 652 657 2-s2.0-35348960243 10.1016/j.coi.2007.07.020 (Pubitemid 350236805)
20. Steinman L., A brief history of TH 17, the first major revision in the TH 1/ TH 2 hypothesis of T cell-mediated tissue damage. Nature Medicine 2007 13 2 139 145 2-s2.0-33846966636 10.1038/nm1551
21. Ganesan A. P., Johansson M., Ruffell B., Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. The Journal of Immunology 2013 191 4 2009 2017 10.4049/jimmunol.1301317
22. Li Y., Cao Z. Y., Sun B., Effects of IL-17A on the occurrence of lung adenocarcinoma. Cancer Biology & Therapy 2011 12 610 616 10.4161/cbt.12.7.16302
23. Mosmann T. R., Cherwinski H., Bond M. W., Giedlin M. A., Coffman R. L., Two types of murine helper T cell clone-I. Definition according to profiles of lymphokine activities and secreted proteins. The Journal of Immunology 1986 136 7 2348 2357 2-s2.0-0022640843 (Pubitemid 16136806)
24. Anthony R. M., Rutitzky L. I., Urban J. F., Stadecker M. J., Gause W. C., Protective immune mechanisms in helminth infection. Nature Reviews Immunology 2007 7 12 975 987 2-s2.0-36448983633 10.1038/nri2199 (Pubitemid 350166058)
25. Sinigaglia F., D'Ambrosio D., Rogge L., Type I interferons and the Th1/Th2 paradigm. Developmental & Comparative Immunology 1999 23 7-8 657 663 2-s2.0-0032752698 10.1016/S0145-305X(99)00039-7 (Pubitemid 29509755)
26. Gran B., Zhang G.-X., Yu S., Li J., Chen X.-H., Ventura E. S., Kamoun M., Rostami A., IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: Evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. The Journal of Immunology 2002 169 12 7104 7110 2-s2.0-0037114150 (Pubitemid 36899299)
27. Vitolo D., Ciocci L., Ferrauti P., Tiboni F., Cicerone E., Gallo A., de Vincentiis M., Baroni C. D., Interleukin-12-related cytokine gene expression in carcinomas of the breast, lung, and larynx: a study at tissue level. Cancer Detection and Prevention 2000 24 5 422 434 2-s2.0-0033676224
28. Echchakir H., Asselin-Paturel C., Dorothee G., Analysis of T-cell-receptor β -chain-gene usage in peripheral-blood and tumor-infiltrating lymphocytes from human non-small-cell lung carcinomas. International Journal of Cancer 1999 81 2 205 213 (Pubitemid 29144748)
29. Baleeiro R. B., Anselmo L. B., Soares F. A., Pinto C. A. L., Ramos O., Gross J. L., Haddad F., Younes R. N., Tomiyoshi M. Y., Bergami-Santos P. C., Barbuto J. A. M., High frequency of immature dendritic cells and altered in situ production of interleukin-4 and tumor necrosis factor- α in lung cancer. Cancer Immunology, Immunotherapy 2008 57 9 1335 1345 2-s2.0-45849151085 10.1007/s00262-008-0468-7
30. Li X., Shi W., Yu G., Interleukin-4-590 T/C polymorphism influences the susceptibility to nonsmall cell lung cancer. DNA and Cell Biology 2012 31 5 797 800 10.1089/dna.2011.1425
31. Li R., Rüttinger D., Li R., Si L.-S., Wang Y.-L., Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer. Langenbeck's Archives of Surgery 2003 388 6 406 412 10.1007/s00423-003-0416-0 (Pubitemid 37509461)
32. Reppert S., Boross I., Koslowski M., Türeci Ö., Koch S., Lehr H. A., Finotto S., A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. Nature Communications 2011 2 1, article 600 2-s2.0-84455203145 10.1038/ncomms1609
33. Hagenbaugh A., Sharma S., Dubinett S. M., Wei S. H.-Y., Aranda R., Cheroutre H., Fowell D. J., Binder S., Tsao B., Locksley R. M., Moore K. W., Kronenberg M., Altered immune responses in interleukin 10 transgenic mice. Journal of Experimental Medicine 1997 185 12 2101 2110 2-s2.0-0030942666 10.1084/jem.185.12.2101 (Pubitemid 27265994)
34. Gough D. J., Levy D. E., Johnstone R. W., Clarke C. J., IFN γ signaling-does it mean JAK-STAT? Cytokine & Growth Factor Reviews 2008 19 5 383 394 2-s2.0-56949089974 10.1016/j.cytogfr.2008.08.004
35. Young H. A., Bream J. H., IFN- γ: recent advances in understanding regulation of expression, biological functions, and clinical applications. Current Topics in Microbiology and Immunology 2007 316 97 117 2-s2.0-38449105556
36. El Hage F., Vergnon I., Grunenwald D., Soria J. C., Chouaib S., Mami-Chouaib F., Generation of diverse mutated tumor antigen-specific cytotoxic T lymphocytes in a lung cancer patient with long survival. Oncology Reports 2005 14 3 763 769 2-s2.0-24644434451
37. Dennis K. L., Blatner N. R., Gounari F., Khazaie K., Current status of interleukin-10 and regulatory T-cells in cancer. Current Opinion in Oncology 2013 25 6 637 645 10.1097/CCO.0000000000000006
38. Huang M., Wang J., Lee P., Sharma S., Mao J. T., Meissner H., Uyemura K., Modlin R., Wollman J., Dubinett S. M., Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Research 1995 55 17 3847 3853 2-s2.0-0029124129
39. Wojciechowska-Lacka A., Matecka-Nowak M., Adamiak E., Lacki J. K., Cerkaska-Gluszak B., Serum levels of interleukin-10 and interleukin-6 in patients with lung cancer. Neoplasma 1996 43 3 155 158 2-s2.0-0029901038 (Pubitemid 26229349)
40. Stewart C. A., Metheny H., Iida N., Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. The Journal of Clinical Investigation 2013 123 11 4859 4874 10.1172/JCI65180
41. +CD2 5- T cells through Foxp3 induction and down-regulation of Smad7. The Journal of Immunology 2004 172 9 5149 5153 2-s2.0-2142645808 (Pubitemid 38542009)
42. + regulatory T cell-mediated immunosuppression. Cytokine & Growth Factor Reviews 2003 14 2 85 89 2-s2.0-0037379654 10.1016/S1359-6101(03)00003-0 (Pubitemid 36389522)
43. Peck A., Mellins E. D., Plasticity of T-cell phenotype and function: the T helper type 17 example. Immunology 2010 129 2 147 153 2-s2.0-73949121455 10.1111/j.1365-2567.2009.03189.x
44. + suppressor T cells: more questions than answers. Nature Reviews Immunology 2002 2 6 389 400 2-s2.0-0036597371 (Pubitemid 37328746)
45. von Boehmer H., Mechanisms of suppression by suppressor T cells. Nature Immunology 2005 6 4 338 344 2-s2.0-16844362608 10.1038/ni1180 (Pubitemid 41716770)
46. Whiteside T. L., Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunology, Immunotherapy 2014 63 1 67 72 10.1007/s00262-013-1490-y
47. + T cell lineage differentiation. Immunity 2009 30 5 646 655 2-s2.0-65549115862 10.1016/j.immuni.2009.05.001
48. + Treg cell conversion of naive T cells. Immunity 2009 30 4 471 472 2-s2.0-64049110576 10.1016/j.immuni.2009.03.008
49. +CD4 4hi cells. Immunity 2008 29 5 758 770 2-s2.0-55549084247 10.1016/j.immuni.2008.09.018
50. +T cells: evidence for two distinct regulatory mechanisms. European Journal of Immunology 2001 31 6 1637 1645 (Pubitemid 32547325)
51. Woo E. Y., Yeh H., Chu C. S., Schlienger K., Carroll R. G., Riley J. L., Kaiser L. R., June C. H., Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. The Journal of Immunology 2002 168 9 4272 4276 2-s2.0-0036569127 (Pubitemid 34441324)
52. Erfani N., Mehrabadi S. M., Ghayumi M. A., Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer 2012 77 2 306 311 10.1016/j.lungcan.2012.04.011
53. Domagała-Kulawik J., Hoser G., Safianowska A., Grubek-Jaworska H., Chazan R., Elevated TGF- β 1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer. Archivum Immunologiae et Therapiae Experimentalis 2006 54 2 143 147 2-s2.0-33747467209 10.1007/s00005-006-0016-0 (Pubitemid 44257351)
54. Carpagnano G. E., Spanevello A., Curci C., Salerno F., Palladino G. P., Resta O., di Gioia G., Carpagnano F., Foschino Barbaro M. P., IL-2, TNF- α and leptin: local versus systemic concentrations in NSCLC patients. Oncology Research 2007 16 8 375 381 2-s2.0-34548687010 (Pubitemid 47413253)
55. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Research 2001 61 12 4766 4772 2-s2.0-0035874949 (Pubitemid 32691889)
56. de Visser K. E., Kast W. M., Effects of TGF- β on the immune system: implications for cancer immunotherapy. Leukemia 1999 13 8 1188 1199 2-s2.0-0032868805 (Pubitemid 29396578)
57. + immunoregulatory T cells that control autoimmune diabetes. Immunity 2000 12 4 431 440 2-s2.0-0033682056
58. + T cells. Journal of Experimental Medicine 1998 188 10 1849 1857 2-s2.0-0032538819 10.1084/jem.188.10.1849 (Pubitemid 28536772)
59. + regulatory T lymphocytes in malignant pleural effusion. American Journal of Respiratory and Critical Care Medicine 2005 172 11 1434 1439 2-s2.0-30344474268 10.1164/rccm.200504-588OC (Pubitemid 43069817)
60. Ganesan A. P., Johansson M., Ruffell B., Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. The Journal of Immunology 2013 191 4 2009 2017 10.4049/jimmunol.1301317
61. Zhao L., Yang J., Wang H. P., Liu R. Y., Imbalance in the Th17/Treg and cytokine environment in peripheral blood of patients with adenocarcinoma and squamous cell carcinoma. Medical Oncology 2013 30 1, article 461 10.1007/s12032-013-0461-7
62. Qin X.-J., Shi H.-Z., Deng J.-M., Liang Q.-L., Jiang J., Ye Z.-J., CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clinical Cancer Research 2009 15 7 2231 2237 2-s2.0-65249151350 10.1158/1078-0432.CCR-08-2641
63. + T regulatory cells suppress NK cell-mediated immunotherapy of cancer. The Journal of Immunology 2006 176 3 1582 1587 2-s2.0-31144468294 (Pubitemid 43134302)
64. + regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006 107 12 2866 2872 2-s2.0-33845590308 10.1002/cncr.22282 (Pubitemid 44937041)
65. + regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. Journal of Thoracic Oncology 2010 5 5 585 590 2-s2.0-77951877847 10.1097/JTO.0b013e3181d60fd7
66. Liu H., Zhang T., Ye J., Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunology, Immunotherapy 2012 61 10 1849 1856 10.1007/s00262-012-1231-7
67. Bettelli E., Carrier Y., Gao W., Korn T., Strom T. B., Oukka M., Weiner H. L., Kuchroo V. K., Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006 441 7090 235 238 2-s2.0-33646577466 10.1038/nature04753
68. Veldhoen M., Hocking R. J., Atkins C. J., Locksley R. M., Stockinger B., TGF β in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006 24 2 179 189 2-s2.0-32244442562 10.1016/j.immuni.2006.01.001 (Pubitemid 43214587)
69. Dong C., TH17 cells in development: an updated view of their molecular identity and genetic programming. Nature Reviews Immunology 2008 8 5 337 348 2-s2.0-42649115767 10.1038/nri2295 (Pubitemid 351595217)
70. Zúñiga L. A., Jain R., Haines C., Cua D. J., Th17 cell development: from the cradle to the grave. Immunological Reviews 2013 252 1 78 88 10.1111/imr.12036
71. + T helper cells. Cell 2006 126 6 1121 1133 2-s2.0-33748588423 10.1016/j.cell.2006.07.035 (Pubitemid 44380299)
72. Yang X. O., Panopoulos A. D., Nurieva R., Seon H. C., Wang D., Watowich S. S., Dong C., STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. The Journal of Biological Chemistry 2007 282 13 9358 9363 2-s2.0-34247593586 10.1074/jbc.C600321200 (Pubitemid 47104613)
73. Mangan P. R., Harrington L. E., O'Quinn D. B., Transforming growth factor- β induces development of the TH 17 lineage. Nature 2006 441 7090 231 234 10.1038/nature04754
74. Acosta-Rodriguez E. V., Napolitani G., Lanzavecchia A., Sallusto F., Interleukins 1 β and 6 but not transforming growth factor- β are essential for the differentiation of interleukin 17-producing human T helper cells. Nature Immunology 2007 8 9 942 949 2-s2.0-34548125305 10.1038/ni1496 (Pubitemid 47300008)
75. Wilson N. J., Boniface K., Chan J. R., McKenzie B. S., Blumenschein W. M., Mattson J. D., Basham B., Smith K., Chen T., Morel F., Lecron J.-C., Kastelein R. A., Cua D. J., McClanahan T. K., Bowman E. P., Malefyt R. D. W., Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nature Immunology 2007 8 9 950 957 2-s2.0-34548133583 10.1038/ni1497 (Pubitemid 47300009)
76. Korn T., Bettelli E., Oukka M., Kuchroo V. K., IL-17 and Th17 cells. Annual Review of Immunology 2009 27 485 517 2-s2.0-61949463911 10.1146/annurev.immunol.021908.132710
77. Rouvier E., Luciani M.-F., Mattei M.-G., Denizot F., Golstein P., CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus Saimiri gene. The Journal of Immunology 1993 150 12 5445 5456 2-s2.0-0027215897 (Pubitemid 23180658)
78. Kawaguchi M., Adachi M., Oda N., Kokubu F., Huang S.-K., IL-17 cytokine family. The Journal of Allergy and Clinical Immunology 2004 114 6 1265 1273 2-s2.0-9744278996 10.1016/j.jaci.2004.10.019 (Pubitemid 39585195)
79. Michel M.-L., Mendes-da-Cruz D., Keller A. C., Lochner M., Schneider E., Dy M., Eberl G., Leite-de-Moraes M. C., Critical role of ROR- γ t in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation. Proceedings of the National Academy of Sciences of the United States of America 2008 105 50 19845 19850 2-s2.0-58149384437 10.1073/pnas.0806472105
80. + T cells. The Journal of Immunology 2009 182 9 5296 5305 2-s2.0-66949180111 10.4049/jimmunol.0900036
81. + T cells are associated with graft-versus-host disease after allogeneic stem cell transplantation. PLoS ONE 2012 7 12 e50896 10.1371/journal.pone.0050896
82. Shibata K., Yamada H., Nakamura M., Hatano S., Katsuragi Y., Kominami R., Yoshikai Y., IFN- γ -producing and IL-17-producing γ δ T cells differentiate at distinct developmental stages in murine fetal thymus. The Journal of Immunology 2014 192 5 2210 2218 10.4049/jimmunol.1302145
83. Michel M.-L., Keller A. C., Paget C., Fujio M., Trottein F., Savage P. B., Wong C.-H., Schneider E., Dy M., Leite-de-Moraes M. C., Identification of an IL-17-producing NK1. 1neg iNKT cell population involved in airway neutrophilia. Journal of Experimental Medicine 2007 204 5 995 1001 2-s2.0-34249059942 10.1084/jem.20061551 (Pubitemid 46798144)
84. + neutrophils increase in allergic asthmatic subjects. Allergy, Asthma & Clinical Immunology 2013 9, article 23 10.1186/1710-1492-9-23
85. Numasaki M., Watanabe M., Suzuki T., Takahashi H., Nakamura A., McAllister F., Hishinuma T., Goto J., Lotze M. T., Kolls J., Sasaki H., IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. The Journal of Immunology 2005 175 9 6177 6189 2-s2.0-27144449330 (Pubitemid 41508106)
86. Carmi Y., Rinott G., Dotan S., Elkabets M., Rider P., Voronov E., Apte R. N., Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. The Journal of Immunology 2011 186 6 3462 3471 2-s2.0-79953219421 10.4049/jimmunol.1002901
87. Li Q., Han Y., Fei G., Guo Z., Ren T., Liu Z., IL-17 promoted metastasis of non-small-cell lung cancer cells. Immunology Letters 2012 148 2 144 150 10.1016/j.imlet.2012.10.011
88. He D., Li H., Yusuf N., Elmets C. A., Li J., Mountz J. D., Xu H., IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. The Journal of Immunology 2010 184 5 2281 2288 2-s2.0-77951936316 10.4049/jimmunol.0902574
89. Kryczek I., Wei S., Szeliga W., Vatan L., Zou W., Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009 114 2 357 359 2-s2.0-67651094058 10.1182/blood-2008-09-177360
90. Martin-Orozco N., Muranski P., Chung Y., Yang X. O., Yamazaki T., Lu S., Hwu P., Restifo N. P., Overwijk W. W., Dong C., T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009 31 5 787 798 2-s2.0-70449530422 10.1016/j.immuni.2009.09.014
91. Kobold S., Völk S., Clauditz T., Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells. Journal of Thoracic Oncology 2013 8 8 1032 1042 10.1097/JTO.0b013e31829923c8
92. + T cells in malignant pleural effusion. Cancer Letters 2012 326 1 23 32 10.1016/j.canlet.2012.07.013
93. Lejeune D., Dumoutier L., Constantinescu S., Kruijer W., Schuringa J. J., Renauld J.-C., Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line: pathways that are shared with and distinct from IL-10. The Journal of Biological Chemistry 2002 277 37 33676 33682 2-s2.0-0037072796 10.1074/jbc.M204204200
94. Romerio F., Zella D., MEK and ERK inhibitors enhance the anti-proliferative effect of interferon- α 2b. The FASEB Journal 2002 16 12 1680 1682 2-s2.0-0036777854
95. Wu J. J., Zhang X. D., Gillespie S., Hersey P., Selection for TRAIL resistance results in melanoma cells with high proliferative potential. FEBS Letters 2005 579 9 1940 1944 2-s2.0-15544371288 10.1016/j.febslet.2005.02.041 (Pubitemid 40404035)
96. Fang J. Y., Richardson B. C., The MAPK signalling pathways and colorectal cancer. The Lancet Oncology 2005 6 5 322 327 2-s2.0-17844368327 10.1016/S1470-2045(05)70168-6 (Pubitemid 40590269)
97. + regulatory T cells in small cell lung cancer reflects disease stage. Clinical Cancer Research 2008 14 21 6770 6779 2-s2.0-58149234402 10.1158/1078-0432.CCR-08-1156
98. + T cells in malignant pleural effusion. The Journal of Immunology 2010 185 10 6348 6354 2-s2.0-78650636066 10.4049/jimmunol.1001728
99. Zou W., Restifo N. P., T H 17 cells in tumour immunity and immunotherapy. Nature Reviews Immunology 2010 10 4 248 256 2-s2.0-77950196277 10.1038/nri2742
100. Martin-Orozco N., Muranski P., Chung Y., Yang X. O., Yamazaki T., Lu S., Hwu P., Restifo N. P., Overwijk W. W., Dong C., T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009 31 5 787 798 2-s2.0-70449530422 10.1016/j.immuni.2009.09.014
101. + regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism. Respiratory Research 2011 12, article 77 2-s2.0-79958155356 10.1186/1465-9921-12-77
102. de Jong E., Suddason T., Lord G. M., Translational mini-review series on Th17 Cells: development of mouse and human T helper 17 cells. Clinical & Experimental Immunology 2010 159 2 148 158 2-s2.0-72949103063 10.1111/j.1365-2249.2009.04041.x
103. Peck A., Mellins E. D., Plasticity of T-cell phenotype and function: the T helper type 17 example. Immunology 2010 129 2 147 153 2-s2.0-73949121455 10.1111/j.1365-2567.2009.03189.x
104. Crome S. Q., Wang A. Y., Levings M. K., Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clinical & Experimental Immunology 2010 159 2 109 119 2-s2.0-72949107811 10.1111/j.1365-2249.2009.04037.x
105. Acosta-Rodriguez E. V., Rivino L., Geginat J., Jarrossay D., Gattorno M., Lanzavecchia A., Sallusto F., Napolitani G., Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nature Immunology 2007 8 6 639 646 2-s2.0-34249079176 10.1038/ni1467 (Pubitemid 46785128)
106. Chen Z., Lin F., Gao Y., Li Z., Zhang J., Xing Y., Deng Z., Yao Z., Tsun A., Li B., FOXP3 and ROR γ t: transcriptional regulation of Treg and Th17. International Immunopharmacology 2011 11 5 536 542 2-s2.0-79954632692 10.1016/j.intimp.2010.11.008
107. Koenen H. J., Smeets R. L., Vink P. M., van Rijssen E., Boots A. M. H., Joosten I., Human CD2 5high Foxp 3pos regulatory T cells differentiate into IL-17 producing cells. Blood 2008 112 6 2340 2352 2-s2.0-55149094300 10.1182/blood-2008-01-133967
108. Zhou L., Lopes J. E., Chong M. M. W., Ivanov I. I., Min R., Victora G. D., Shen Y., Du J., Rubtsov Y. P., Rudensky A. Y., Ziegler S. F., Littman D. R., TGF- Β -induced Foxp3 inhibits TH 17 cell differentiation by antagonizing ROR γ t function. Nature 2008 453 7192 236 240 2-s2.0-43449135305 10.1038/nature06878 (Pubitemid 351667978)
109. Yang X. O., Nurieva R., Martinez G. J., Kang H. S., Chung Y., Pappu B. P., Shah B., Chang S. H., Schluns K. S., Watowich S. S., Feng X.-H., Jetten A. M., Dong C., Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008 29 1 44 56 2-s2.0-46749138596 10.1016/j.immuni.2008.05.007
110. q correlates to expression of the transforming growth factor β type II receptor in a panel of small cell lung cancer cell lines. Lung Cancer 1998 20 1 65 69 2-s2.0-0031713282 10.1016/S0169-5002(98)00013-0 (Pubitemid 28473183)
111. Jeon H.-S., Jen J., TGF- β signaling and the role of inhibitory smads in non-small cell lung cancer. Journal of Thoracic Oncology 2010 5 4 417 419 2-s2.0-77950977675 10.1097/JTO.0b013e3181ce3afd
112. Hasegawa Y., Takanashi S., Kanehira Y., Tsushima T., Imai T., Okumura K., Transforming growth factor- β 1 level correlates with angiogenesis, tumor progression, and prognosis in patients with non-small cell lung carcinoma. Cancer 2001 91 5 964 971
113. Roberts A. B., Wakefield L. M., The two faces of transforming growth factor β in carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America 2003 100 15 8621 8623 2-s2.0-0042307513 10.1073/pnas.1633291100 (Pubitemid 36899145)
114. Yosef N., Shalek A. K., Gaublomme J. T., Dynamic regulatory network controlling TH 17 cell differentiation. Nature 2013 496 7446 461 468 10.1038/nature11981
115. Grivennikov S. I., Greten F. R., Karin M., Immunity, inflammation, and cancer. Cell 2010 140 6 883 899 2-s2.0-77950346282 10.1016/j.cell.2010.01.025
116. Mantovani A., Allavena P., Sica A., Balkwill F., Cancer-related inflammation. Nature 2008 454 7203 436 444 2-s2.0-47949096781 10.1038/nature07205
117. Ostrand-Rosenberg S., Immune surveillance: a balance between protumor and antitumor immunity. Current Opinion in Genetics & Development 2008 18 1 11 18 2-s2.0-43749102276 10.1016/j.gde.2007.12.007 (Pubitemid 351694442)
118. DeNardo D. G., Andreu P., Coussens L. M., Interactions between lymphocytes and myeloid cells regulate pro-versus anti-tumor immunity. Cancer and Metastasis Reviews 2010 29 2 309 316 2-s2.0-77954563614 10.1007/s10555-010- 9223-6
119. Drexler S. K., Yazdi A. S., Complex roles of inflammasomes in carcinogenesis. Cancer Journal 2013 19 6 468 472 10.1097/PPO.0000000000000004